Oncopharmpod

Gilteritinib

Informações:

Synopsis

Another week, another FDA-approval for AML. We discuss the latest in #oncopharm approvals: the FLT3-inhibitor gilteritinib. For more background reading, try here: https://doi.org/10.1177%2F1078155218802620

Join Now

Join Now

  • Unlimited access to all content on the platform.
  • More than 30 thousand titles, including audiobooks, ebooks, podcasts, series and documentaries.
  • Narration of audiobooks by professionals, including actors, announcers and even the authors themselves.
Try it Now Firm without compromise. Cancel whenever you want.

Share